Literature DB >> 16109079

Octreotide therapy for chylous ascites in a chronic dialysis patient.

Pei-Hsien Lee1, Chun-Liang Lin, Ping-Chin Lai, Chih-Wei Yang.   

Abstract

Chylous ascites, a rare complication in patients receiving continuous peritoneal dialysis, often presents with turbid dialysate. This characteristic makes it frequently confused with peritonitis. Conservative treatments including bowel rest and dietary intervention with medium chain triglycerides are advised by many authors in the literature. However, this approach usually takes a long time before the lymphorrhagia are eventually resolved. Here, a case of chylous ascites that was successfully treated with subcutaneous octreotide, a somatostatin analogue, is reported. By shortening the bowel rest period, this treatment avoids the nutritional and immunological adverse effects. A series of peritoneal equilibrium tests were performed after administration of octreotide and the results showed that octreotide did not alter the peritoneal function in the short term. Therefore, subcutaneous octreotide administration is a safe and effective therapy in peritoneal dialysis patient with chylous ascites.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109079     DOI: 10.1111/j.1440-1797.2005.00427.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  6 in total

1.  Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda Page; David R Holmes; Xujian Li; Eric J Bergstralh; Maria V Irazabal; Bohyun Kim; Bernard F King; James F Glockner; Nicholas F Larusso; Vicente E Torres
Journal:  Nephrol Dial Transplant       Date:  2012-07-06       Impact factor: 5.992

2.  Chyloperitoneum in pediatric peritoneal dialysis: rapid remission after introduction of medium-chain triglyceride-based formula.

Authors:  J Lanneaux; A Davourie-Salandre; E Tudorache; I Stoica; B Aoun; T Ulinski
Journal:  Perit Dial Int       Date:  2013 May-Jun       Impact factor: 1.756

3.  Resolution of chyloperitoneum in a preterm with octreotide, diet and cessation of dialysis.

Authors:  Alper Soylu; Demet Alaygut; Didem Yeşilirmak; Belde Kasap; Mehmet Türkmen; Nuray Duman; Salih Kavukçu
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

4.  The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis.

Authors:  Dong Xun Zhou; Hua Bang Zhou; Qing Wang; Shan Shan Zou; Hao Wang; He Ping Hu
Journal:  Dig Dis Sci       Date:  2008-12-03       Impact factor: 3.199

5.  Recurrent chyloperitoneum: a rare complication of peritoneal dialysis.

Authors:  Juhi Kumar; Roberto Gordillo; Marcela Del Rio; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2007-12-19       Impact factor: 3.714

Review 6.  Established and potential therapeutic applications of octreotide in palliative care.

Authors:  Eric E Prommer
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.